Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
- 15 January 2010
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 950-955
Abstract
Background Patients with poor-risk Waldenström’s macroglobulinemia have suboptimal response and early post-treatment relapse with conventional therapies. Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients. Design and Methods We examined the long-term outcome of allogeneic stem cell transplantation in Waldenström’s macroglobulinemia by studying the records of 24 patients reported in the SFGM-TC database and one transplanted in the bone marrow unit in Hamburg. Results Median age at the time of transplant was 48 years (range, 24–64). The patients had previously received a median of 3 lines of therapy (range, 1–6) and 44% of them had refractory disease at time of transplant. Allogeneic stem cell transplantation after myeloablative (n=12) or reduced-intensity (n=13) conditioning yielded an overall response rate of 92% and immunofixation-negative complete remission in 50% of evaluable patients. With a median follow-up of 64 months among survivors (range, 11–149 months), 5-year overall survival and progression-free survival rates were respectively, 67% (95% CI: 46–81) and 58% (95% CI: 38–75). The 5-year estimated risk of progression was 25% (95% CI: 10–36%), with only one relapse among the 12 patients who entered complete remission, versus 5 in the 12 patients who did not. Only one of the 6 relapses occurred more than three years post-transplant. Conclusions Allogeneic stem cell transplantation yields a high rate of complete remissions and is potentially curative in poor-risk Waldenström’s macroglobulinemia.Keywords
This publication has 12 references indexed in Scilit:
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantationBone Marrow Transplantation, 2007
- Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensusLeukemia, 2006
- Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstrom’s MacroglobulinemiaTransplantation and Cellular Therapy, 2006
- Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2006
- Transplantation in Waldenstrom's macroglobulinemia—the French experienceSeminars in Oncology, 2003
- Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopeniaBone Marrow Transplantation, 2001
- High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemiaBone Marrow Transplantation, 2001
- Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemiaBone Marrow Transplantation, 1999
- Allogenic transplantation of mobilized peripheral blood progenitor cells: towards tailored cell therapy.1997